US Patent Issued to BIOMARIN TECHNOLOGIES on June 17 for "Bispecific antisense oligonucleotides for dystrophin exon skipping" (Dutch Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,293, issued on June 17, was assigned to BIOMARIN TECHNOLOGIES B.V. (Amsterdam).

"Bispecific antisense oligonucleotides for dystrophin exon skipping" was invented by Judith Christina Theodora van Deutekom (Dordrecht, Netherlands) and Nicole Anne Datson (Oegstgeest, Netherlands).

According to the abstract* released by the U.S. Patent & Trademark Office: "The current invention provides splice-switching compounds with improved characteristics that enhance clinical applicability preferably for treating, ameliorating, preventing, and/or delaying neuromuscular disorders, more specifically DMD."

The patent was filed on Oct. 30, 2019, under Application No. 17/309,140.

*For further infor...